Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, May 25, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that the scientific journal Vaccines published an article authored by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis.
Excerpt: "…the data suggest that a cVLP-based vaccine displaying full-length IL-1β represents a promising vaccine candidate for use as an alternative treatment modality against severe ACD."
The scientific article is titled "Preclinical Efficacy of a Capsid Virus-Like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis". Paper reference: Goksøyr, L. et al., Vaccines 2022, 10, 828. https://doi.org/10.3390/vaccines10050828. The article can also be found via this link (https://www.mdpi.com/2076-393X/10/5/828).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se